Half-year report · Q2
6095.TEDINET S100VQUM
Period2024-10-01 → 2025-03-31
Filed2025-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥629m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥14.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥149m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥93m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥360m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.65 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | revenue external | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | segment profit | 2024-10-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥683m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥964m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥72m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥393m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥38m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥6.2bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥74m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥1.3bn |
| Otherother segments | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| Otherother segments | segment profit | 2023-10-01 → 2024-03-31 | ¥159m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥679m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥967m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥10m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥520m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥6.7bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥23m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人 トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)滝沢 勝己 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)萬 政広 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 7850221000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 6312369000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 14948380000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 831274000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 654336000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1264298000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 199278000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 426732000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1481764000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 212652000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 433874000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1503356000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 8726222000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 9798494000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 9451350000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 14900928000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 14813864000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 15554738000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 9.18 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 19.65 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 68.26 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.565 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.661 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.607 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 806693000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 149403000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1890649000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -47413000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | 92531000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 1266124000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -378394000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -360419000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -1269931000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 5774053000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 7161525000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 7280009000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 22010330 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 22010330 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 22010330 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 22010330 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 5315490 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2446 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |